Chromodomain Helicase DNA Binding Proteins (CHD proteins) are critical players in the regulation of chromatin architecture, contributing to processes such as DNA repair, transcription, and replication. These proteins possess both chromodomains for binding to specific histone marks and helicase domains for unwinding DNA, allowing them to rearrange chromatin structure and thereby modulate gene expression. CHD proteins often act as part of larger multi-protein complexes, and their activity can be regulated through post-translational modifications like phosphorylation, acetylation, or ubiquitination. Their roles intersect with various cellular signaling pathways, such as Wnt/β-catenin, MAPK, and PI3K/AKT, to translate extracellular signals into changes in gene expression via chromatin remodeling.
CHD proteins facilitate the rearrangement of chromatin structure, thereby impacting DNA accessibility for various cellular processes such as transcription, DNA repair, and replication. Small molecules in this category work to either directly stimulate CHD enzymatic activity or influence pathways that result in their upregulation. The direct activators may function by binding to specific domains of CHD proteins, thereby enhancing their helicase or ATPase activities. Some of these molecules could be allosteric modulators that bind to regulatory sites distinct from the active sites, thus fine-tuning the proteins' functionalities. Because CHD proteins have different isoforms with diverse functions and tissue distributions, the small molecules within this category may also display isoform specificity. Overall, the intricate nature of chromatin dynamics makes the activity of these activators highly context-dependent and subject to various layers of cellular regulation.
VOIR ÉGALEMENT...
Nom du produit | CAS # | Ref. Catalogue | Quantité | Prix HT | CITATIONS | Classement |
---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
La trichostatine A et l'acide valproïque, par exemple, pourraient affecter la structure de la chromatine et augmenter indirectement les protéines CHD. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $85.00 | 9 | |
La trichostatine A et l'acide valproïque, par exemple, pourraient affecter la structure de la chromatine et augmenter indirectement les protéines CHD. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $214.00 $316.00 $418.00 | 7 | |
Les inhibiteurs de l'ADN méthyltransférase pourraient également avoir un impact sur le paysage chromatinien, et donc potentiellement sur les protéines CHD. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Les inhibiteurs de PI3K/AKT/mTOR pourraient influencer indirectement l'expression ou l'activation des protéines CHD via des cascades de signalisation qui affectent la transcription. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
Les inhibiteurs de PI3K/AKT/mTOR pourraient influencer indirectement l'expression ou l'activation des protéines CHD via des cascades de signalisation qui affectent la transcription. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Les inhibiteurs de PI3K/AKT/mTOR pourraient influencer indirectement l'expression ou l'activation des protéines CHD via des cascades de signalisation qui affectent la transcription. | ||||||
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $60.00 $270.00 $350.00 | 48 | |
Les activateurs de l'AMPK pourraient indirectement influencer les protéines de la maladie cardiovasculaire par le biais de la régulation de l'énergie et des effets conséquents sur la transcription. | ||||||
C646 | 328968-36-1 | sc-364452 sc-364452A | 10 mg 50 mg | $260.00 $925.00 | 5 | |
L'inhibiteur de P300/CBP pourrait affecter l'état d'acétylation des histones et ainsi influencer l'activité ou l'expression de la protéine CHD. |